Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study
- 1 June 1984
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (6) , 777-782
- https://doi.org/10.1016/0277-5379(84)90216-5
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.Journal of Clinical Oncology, 1984
- Small cell lung cancer and the influence of chemotherapy on CFUcs in bone marrowCancer, 1984
- Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detectionJournal of Pharmaceutical and Biomedical Analysis, 1983
- Autologous cryopreserved platelets and prophylaxis of bleeding in autologous bone marrow transplantationAnnals of Hematology, 1983
- AUTOLOGOUS BONE MARROW RESCUE IS UNNECESSARY AFTER VERY-HIGH-DOSE CYCLOPHOSPHAMIDEThe Lancet, 1983
- Enteral nutrition by nasogastric tube in adult patients treated with intensive chemotherapy for acute leukemiaThe American Journal of Clinical Nutrition, 1982
- Dose: A critical factor in cancer chemotherapyThe American Journal of Medicine, 1980
- Infection prevention in granulocytopenic patients by selective decontamination of the digestive tractPublished by Elsevier ,1980